Q1 EPS Estimate for Axsome Therapeutics Reduced by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at HC Wainwright reduced their Q1 2026 earnings estimates for Axsome Therapeutics in a note issued to investors on Wednesday, February 25th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.70) per share for the quarter, down from their prior forecast of ($0.13). HC Wainwright has a “Buy” rating and a $260.00 price objective on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at $0.73 EPS, FY2026 earnings at ($0.41) EPS, Q1 2027 earnings at $1.77 EPS, Q2 2027 earnings at $2.55 EPS, Q3 2027 earnings at $3.37 EPS, Q4 2027 earnings at $4.17 EPS and FY2027 earnings at $11.87 EPS.

Several other analysts have also recently commented on AXSM. Needham & Company LLC restated a “buy” rating and set a $225.00 target price on shares of Axsome Therapeutics in a report on Monday, February 23rd. Guggenheim upped their price target on shares of Axsome Therapeutics from $205.00 to $220.00 and gave the stock a “buy” rating in a research report on Tuesday. Piper Sandler raised their price objective on shares of Axsome Therapeutics from $148.00 to $223.00 and gave the company an “overweight” rating in a research report on Friday, January 16th. Truist Financial set a $200.00 target price on shares of Axsome Therapeutics in a research note on Monday. Finally, Robert W. Baird set a $209.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, January 13th. Seventeen investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Axsome Therapeutics has an average rating of “Moderate Buy” and an average target price of $216.12.

Axsome Therapeutics Trading Up 0.4%

AXSM stock opened at $163.89 on Friday. The business has a fifty day moving average price of $175.78 and a 200 day moving average price of $146.07. Axsome Therapeutics has a fifty-two week low of $86.99 and a fifty-two week high of $191.50. The stock has a market capitalization of $8.38 billion, a price-to-earnings ratio of -44.41 and a beta of 0.40. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.55 and a quick ratio of 1.50.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.14. The company had revenue of $196.00 million during the quarter, compared to analysts’ expectations of $191.33 million. Axsome Therapeutics had a negative net margin of 28.69% and a negative return on equity of 232.61%. The business’s revenue for the quarter was up 65.0% compared to the same quarter last year.

Insider Buying and Selling

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 35,378 shares of the stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $161.88, for a total value of $5,726,990.64. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mark Coleman sold 25,000 shares of the firm’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $161.11, for a total value of $4,027,750.00. Following the transaction, the director owned 47,140 shares in the company, valued at approximately $7,594,725.40. This trade represents a 34.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 369,252 shares of company stock worth $61,145,545 over the last 90 days. 22.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Stanley Laman Group Ltd. bought a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at about $2,125,000. Vanguard Group Inc. grew its holdings in Axsome Therapeutics by 6.0% during the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock worth $507,739,000 after purchasing an additional 235,626 shares during the period. Aberdeen Group plc increased its position in Axsome Therapeutics by 15.5% during the third quarter. Aberdeen Group plc now owns 94,648 shares of the company’s stock worth $11,495,000 after buying an additional 12,732 shares during the last quarter. Swiss National Bank raised its stake in Axsome Therapeutics by 6.9% in the second quarter. Swiss National Bank now owns 65,200 shares of the company’s stock valued at $6,806,000 after buying an additional 4,200 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in Axsome Therapeutics by 55.4% in the second quarter. Bank of New York Mellon Corp now owns 203,632 shares of the company’s stock valued at $21,257,000 after buying an additional 72,609 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics News Summary

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $260 price target and forecasts a large rebound into FY‑2027 (FY‑2027 EPS of $11.87 with strong quarterly ramps). This upbeat long‑term view supports investor optimism. Read More.
• Positive Sentiment: Recent company results showed a Q4 EPS beat and revenue up ~65% year‑over‑year, which provides fundamental support for the stock despite near‑term model revisions. Read More.
• Neutral Sentiment: Reported short interest data in late February shows effectively zero shares short (the published figures contain anomalies/NaN), so short‑position dynamics appear minimal and unlikely to be a near‑term driver. Read More.
• Negative Sentiment: HC Wainwright trimmed multiple near‑term 2026 estimates (Q1‑Q3 and FY‑2026 materially lowered; Q4‑2026 also revised down from prior forecasts). These cuts signal more modest near‑term profitability than previously expected and increase uncertainty for 2026 results. Read More.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.